Melanotan (one) "afamelanotide" discovery by researchers at the University of Arizona in Tucson as explained by NBC News' Robert Bazell (with Tom Brokaw introduction) in a November 1991 News report. Melanotan (one) is now being developed in Australia as a photoprotective medicine to treat people who's skin is negatively affected (more than normal) by exposure to UV light. Clinuvel (originally named "Epitan") is the company that has been working to develop it since 1999. They are currently conducting clinical trials (under the drug name "afamelanotide"). The expected release of Melanotan one on the market as a treatment option for Erythropoietic Protoporphyria (EPP) sufferers is likely to be either 2009 or 2010.